1,3,4-Trimethyl-1H-pyrazolo<3,4-b>pyridin | 57411-65-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 1,3,4-Trimethyl-1H-pyrazolo<3,4-b>pyridin
• 英文别名: 1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridine；1,3,4-Trimethyl-1H-pyrazolo[3,4-b]pyridine；1,3,4-trimethylpyrazolo[3,4-b]pyridine
• CAS: 57411-65-1
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: LPMURLLPCMXLHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3,4-Trimethyl-1H-pyrazolo<3,4-b>pyridin 以55%的产率得到
  参考文献：
  名称：

  RATAJCZYK J. D.; SWETT L. R., J. HETEROCYCL. CHEM. , 1975, 12, NO 3, 517-522

  摘要：

  DOI：

文献信息

• [EN] NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE<br/>[FR] AGENTS ANTI-GNRH NON PEPTIDIQUES, COMPOSITIONS PHARMACEUTIQUES ET PROCEDES D'UTILISATION
  申请人：PFIZER

  公开号：WO2003106446A1

  公开（公告）日：2003-12-24

  Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression o£ gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

  描述了能够抑制促性腺激素释放激素作用的非肽类GnRH药物。这些化合物及其药用可接受的盐类、前药和活性代谢物适用于治疗哺乳动物的生殖障碍和类固醇激素依赖性肿瘤，以及调节生育能力，其中表明需要抑制促性腺激素释放。还描述了合成这些化合物和在其制备中有用的中间体的方法。
• NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE
  申请人：PFIZER INC.

  公开号：EP1560818A1

  公开（公告）日：2005-08-10
• RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20160311871A1

  公开（公告）日：2016-10-27

  An object to be solved by the present invention is to identify patients resistant to known HSP90 inhibitors, and to provide a novel therapeutic agent for treating the patients who have become resistant to known HSP90 inhibitors. As a means for solving the above problems, the present invention provides identification of the patients based on a protein, which is an HSP90 family protein having a mutation in the site corresponding to F138 of HSP90α class A consisting of the amino acid sequence of SEQ ID NO: 1, and use of a substance that inhibits the protein as an active ingredient of a therapeutic agent.
• RATAJCZYK J. D.; SWETT L. R., J. HETEROCYCL. CHEM. <JHTC-AC>, 1975, 12, NO 3, 517-522
  作者：RATAJCZYK J. D.、 SWETT L. R.

  DOI：——

  日期：——